Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OrthoLogic partnership opportunities

This article was originally published in The Gray Sheet

Executive Summary

Firm's Chrysalis BioTechnology acquisition for $27.5 mil. in cash and stock (plus up to $7 mil. in milestones) stems from an earlier licensing pact for development-phase, Chrysalin synthetic peptide-based therapeutics for orthopedic indications. The purchase provides rights beyond orthopedics: OrthoLogic is considering partnering with a device firm to market a Chrysalin-based cardiovascular drug that could be delivered via catheter for ischemia, CEO Thomas Trotter said April 29. The firm also is pondering partnerships to speed development of five Chrysalin-based products for orthopedic indications (1"The Gray Sheet" Oct. 13, 2003, p. 12)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT020160

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel